{
    "brief_title": "A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer",
    "phase": "Phase 3",
    "drugs": "['XZP-3287+Fulvestrant', 'Placebo + Fulvestrant']",
    "drugs_list": [
        "XZP-3287+Fulvestrant",
        "Placebo + Fulvestrant"
    ],
    "diseases": "['Advanced Breast Cancer']",
    "diseases_list": [
        "Advanced Breast Cancer"
    ],
    "enrollment": "300.0",
    "inclusion_criteria": "inclusion criteria: \n\n Female patients aged \u226518 years and \u226475 years old; \n\n Patient is in the menopausal state\uff1b \n\n Pathologically-confirmed HR positive and Her2 negative Breast Cancer; \n\n Locally advanced stage, recurrence or metastasis breast cancer; 4.1 Disease progression after previous endocrine therapy\uff1b 4.2 One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy; \n\n At least one measurable lesion (based on RECIST v1.1) or only bone metastases; \n\n Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; \n\n Adequate organ and marrow function; \n\n Patient of childbearing age must undergo a serum pregnancy test within 14 days before randomization, and the result is negative; patient is willing to use a medically approved high-efficiency contraceptive method during the study period and within 6 months after the last study drug treatment; \n\n Patient with acute toxic reactions caused by previous anti-tumor treatments or surgical operations were alleviated to grade 0 to 1 (NCI-CTCAE v5.0), or to the level specified by the enrollment criteria; \n\n Patient has signed informed consent before any trial related activities. \n\n ",
    "exclusion_criteria": ": \n\n Patient with visceral crisis, inflammatory breast cancer, or brain metastases, except for patient with stable brain metastases; \n\n Patient had clinically significant pleural effusions, ascites effusions, or pericardial effusions in the 4 weeks before enrollment; \n\n Patient who received prior treatment with mTOR inhibitors, CDK4/6 inhibitors or fulvestrant; \n\n Participation in a prior treatment of major surgery, chemotherapy, radiotherapy, and any anti-tumor treatment within 14 days before enrollment\uff1b \n\n Patient who participated in other clinical trials within 14 days before enrollment or within 5 half-lives of the trial drug, whichever is longer; \n\n Patient used CYP3A4 potent inhibitors or potent inducers within 14 days before enrollment or within 5 half-lives of the drug, whichever is longer; \n\n Patient who used bisphosphonates or RANKL inhibitors within 7 days before enrollment, patient who have started treatment during the study should not change the method of use; \n\n Any other malignant tumor has been diagnosed within 3 years before randomization; \n\n Patient is in the active stage of HBV, HCV or co-infected with HBV, HCV, or Patient with positive HIV antibody; \n\n Patient with severe infection within 4 weeks before enrollment, or unexplained fever> 38.5\u2103 during screening/before enrollment; \n\n Patient with heart function impaired or clinically significant heart disease within 6 months before enrollment; \n\n Cerebrovascular accident occurred within 6 months before enrollment, including history of transient ischemic attack or stroke; symptomatic pulmonary embolism; \n\n Inability to swallow, intestinal obstruction or other factors that affect the taking and absorption of the drug; \n\n Patient with a known hypersensitivity to any of the excipients in this study; \n\n A prior history of autologous or allogeneic hematopoietic stem cell transplantation; \n\n A prior history of psychotropic drug abuse or drug use; \n\n Pregnant or breastfeeding; \n\n The researchers considered that there were some cases that were not suitable for inclusion.",
    "brief_summary": "This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.",
    "NCT_ID": "NCT05077449"
}